ASND · Company research
Ascendis Pharma A/S (ASND): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
26records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| TransCon® CNP (Navepegritid), einmal wöchentlich, erhält eine positive Bewertung des CHMP für die Behandlung von Achondroplasie bei Kindern | Ascendis Pharma announced that the European Medicines Agency's CHMP committee issued a positive opinion for TransCon CNP (Navepegritide), a once-weekly treatment for achondroplasia in children aged 2+ years with open epiphyses. The European Commission is expected to make a final decision in Q4 2026, with market launch in Germany anticipated for Q1 2027 under the brand name YUVIWEL®. The drug was previously approved by the FDA in February 2026. | View source ↗ | GlobeNewswire Inc. | Oct 17, 2026 | bullish | 1 | 1 |
| TransCon® CNP (navepegritide), administré une fois par semaine, reçoit un avis favorable du CHMP dans le traitement de l’achondroplasie chez l’enfant | Ascendis Pharma announced that the European Medicines Agency's CHMP committee issued a positive opinion recommending approval of TransCon CNP (navepegritide) for treating achondroplasia in children aged 2+ with open epiphyses. The European Commission's final decision is expected in Q4 2026, with commercial launch planned in Germany in Q1 2027 under the brand name YUVIWEL®. | View source ↗ | GlobeNewswire Inc. | Oct 17, 2026 | bullish | 1 | 1 |
| ASND Nov 2026 280.000 call (ASND261120C00280000) Stock Historical Prices & Data - Yahoo! Finance Canada | ASND Nov 2026 280.000 call (ASND261120C00280000) Stock Historical Prices & Data Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| ASND Nov 2026 240.000 call (ASND261120C00240000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ASND Nov 2026 240.000 call (ASND261120C00240000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| ASND Jan 2027 240.000 put (ASND270115P00240000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ASND Jan 2027 240.000 put (ASND270115P00240000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| ASND Nov 2026 260.000 call (ASND261120C00260000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ASND Nov 2026 260.000 call (ASND261120C00260000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged - Stocktwits | ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| Employees receive 35,890 warrants from Ascendis Pharma (ASND) at a $223.21 exercise price. - Stock Titan | Employees receive 35,890 warrants from Ascendis Pharma (ASND) at a $223.21 exercise price. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Ascendis Pharma (ASND) Stock May Be Undervalued After Rare Disease Data News - Simply Wall Street | Ascendis Pharma (ASND) Stock May Be Undervalued After Rare Disease Data News Simply Wall Street | View source ↗ | Simply Wall Street | Oct 14, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Oct 14, 2026 | neutral | 0 | 0.6 |
| Here’s How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years - Benzinga | Here’s How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years Benzinga | View source ↗ | Benzinga | Oct 12, 2026 | neutral | 0 | 0.6 |
| Ascendis Pharma (NasdaqGS:ASND) Stock Forecast & Analyst Predictions - Simply Wall Street | Ascendis Pharma (NasdaqGS:ASND) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 9, 2026 | neutral | 0 | 0.6 |
| Ascendis Pharma A/S (ASND) Stock Price, News, Quote & History - Yahoo! Finance Canada | Ascendis Pharma A/S (ASND) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing | BridgeBio Pharma announced FDA acceptance of its regulatory filing for infigratinib, an oral drug to treat achondroplasia in children, with priority review and a decision expected by February 4, 2027. The drug demonstrated 2.1 cm/year greater height growth than placebo in Phase III trials. If approved, it would be the first oral therapy for achondroplasia, differentiating it from injectable competitors. BridgeBio also has two other near-term regulatory catalysts (BBP-418 and encaleret) that could diversify its revenue beyond its current marketed product Attruby. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.333 | 1 |
| FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing | BridgeBio Pharma announced FDA acceptance of its regulatory filing for infigratinib, an oral drug to treat achondroplasia in children, with priority review and a decision expected by February 4, 2027. The drug demonstrated 2.1 cm/year greater height growth than placebo in Phase III trials. If approved, it would be the first oral therapy for achondroplasia, differentiating it from injectable competitors. BridgeBio also has two other near-term regulatory catalysts (BBP-418 and encaleret) that could diversify its revenue beyond its current marketed product Attruby. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.333 | 1 |
| Bone mass normalized over five years in treated patients. Ascendis will present the data in Boston. - Stock Titan | Bone mass normalized over five years in treated patients. Ascendis will present the data in Boston. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| ASND Dec 2027 310.000 put (ASND271217P00310000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ASND Dec 2027 310.000 put (ASND271217P00310000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 5, 2026 | neutral | 0 | 0.6 |
| ASND Oct 2026 300.000 call (ASND261016C00300000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ASND Oct 2026 300.000 call (ASND261016C00300000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 5, 2026 | neutral | 0 | 0.6 |
| ASND Dec 2026 165.000 put (ASND261218P00165000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ASND Dec 2026 165.000 put (ASND261218P00165000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 5, 2026 | neutral | 0 | 0.6 |
| ASND Apr 2027 230.000 put (ASND270416P00230000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ASND Apr 2027 230.000 put (ASND270416P00230000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 5, 2026 | neutral | 0 | 0.6 |
| Ascendis Pharma (NasdaqGS:ASND) Stock Price - Simply Wall Street | Ascendis Pharma (NasdaqGS:ASND) Stock Price Simply Wall Street | View source ↗ | Simply Wall Street | Oct 3, 2026 | neutral | 0 | 0.6 |
| Ascendis Pharma (ASND) Authorizes $400M Share Buyback - Yahoo Finance | Ascendis Pharma (ASND) Authorizes $400M Share Buyback Yahoo Finance | View source ↗ | Yahoo Finance | Sep 20, 2026 | neutral | 0 | 0.6 |
| Ascendis Pharma (ASND) Stock Looks Near Fair Value On Infant Trial Data - Simply Wall Street | Ascendis Pharma (ASND) Stock Looks Near Fair Value On Infant Trial Data Simply Wall Street | View source ↗ | Simply Wall Street | Sep 18, 2026 | neutral | 0 | 0.6 |
| Why Ascendis Pharma (ASND) Stock Is Up Today - Quiver Quantitative | Why Ascendis Pharma (ASND) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 31, 2026 | neutral | 0 | 0.6 |
| Ascendis agrees to pay BioMarin 20% of U.S. YUVIWEL net sales - Stock Titan | Ascendis agrees to pay BioMarin 20% of U.S. YUVIWEL net sales Stock Titan | View source ↗ | Stock Titan | Aug 31, 2026 | neutral | 0 | 0.6 |
| Ascendis Pharma (NasdaqGS:ASND) Stock Turns Profitable As YORVIPATH Drives Growth - Simply Wall Street | Ascendis Pharma (NasdaqGS:ASND) Stock Turns Profitable As YORVIPATH Drives Growth Simply Wall Street | View source ↗ | Simply Wall Street | Aug 15, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.